Background: Allogeneic HSCT is generally reserved for high-risk or relapsed hematologic malignancies, while autologous HSCT is used for chemosensitive diseases such as multiple myeloma and certain lymphomas. Allo-HSCT: Infusion of hematopoietic cells from a HLA-compatible donor after cytotoxic conditioning to eradicate disease and enable engraftment. Common indications of HSCT in classic hematology: Severe aplastic anemia Hemoglobinopathies (sickle cell disease, β-thalassemia